Description: 9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products. The company is based in Raleigh, North Carolina.
Home Page: www.9meters.com
NMTR Technical Analysis
8480 Honeycutt Road
Raleigh,
NC
27615
United States
Phone:
919 275 1933
Officers
| Name | Title |
|---|---|
| Mr. John Temperato | Pres, CEO & Director |
| Ms. Bethany Sensenig C.M.A., M.B.A. | Chief Financial Officer |
| Mr. Sireesh Appajosyula Pharm.D. | Sr. VP of Corp. Devel. & Operations |
| Mr. Albert J. Medwar M.B.A., MBA | Sr. VP of Investor Relations & Corp. Communications |
| Jerry Gardner | Head of Clinical Strategy |
| Dr. Patrick H. Griffin | Chief Medical Officer |
| Dr. Nir Barak M.D. | Sr. VP of Scientific Affairs |
| Ms. Sarah Liu M.B.A. | Chief Commercial Officer |
| Dr. Peter H. R. Green M.D. | Clinical & Scientific Advisor and Consultant |
| Mr. Joseph A. Murray M.D. | Clinical & Scientific Advisor and Consultant |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5881 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2016-07-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 21 |